Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Business people run on the arrows. Business concept of competition or target aiming. Flat vector illustration.

Leadership

BBOT shakes up leadership as RAS competitors get more visibility

Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes a busy period of clinical advancement in the RAS oncology space.

April 23, 2026

2 min read

Annalee Armstrong

Progress success promotion and career growth Goal achievement, business woman walks up the stairs to the illuminated arrow. isometric vector illustration.

Earnings

Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure of CEO Paul Hudson.

April 23, 2026

3 min read

Annalee Armstrong

Composite photo collage of hands hold picket poster riot agitation strike crowd people democracy solidarity isolated on painted background.

Complete response letters

Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters

The FDA in July 2025 made publicly available over 200 complete response letters—an initiative that the investment community sees as “unanimously positive,” analysts told BioSpace.

April 23, 2026

2 min read

Tristan Manalac

Collage halftone banner with two hands that put objects on scales. Halftone hands holding circle and square and put them on the scales. Concept of business balance in teamwork. Vector illustration.

Obesity

Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’

Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks—falling far below analyst and investor expectations.

April 23, 2026

2 min read

Tristan Manalac

View of Chicago Skyline from North Avenue Beach

Neuroscience

AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data

This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for myasthenia gravis.

April 23, 2026

4 min read

Tristan Manalac

USA Map with red pins featuring the Carolinas, specifically Raleigh Durham. Could be used to showcase store locations or represent many locations.

Manufacturing

AbbVie commits $1.4B to NC plant in its largest-ever single campus investment

The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.

April 23, 2026

2 min read

Nick Paul Taylor

Insights

The next era of diabetes management

In this episode of Denatured, you’ll be hearing from Dr. Sarah Howell, CEO at Arecor Therapeutics and Dr. Wendy S. Lane, clinical endocrinologist and diabetologist. We examine how increasingly connected and tailored diabetes technologies are reframing the field’s central opportunity around minimizing the day-to-day demands of managing the condition.

April 23, 2026

1 min read

Jennifer C. Smith-Parker

Photo collage of hands holding large and small coins

Job Trends

Life sciences still falls short on pay equity

Women and nonwhite racial/ethnic groups are still earning less in the life sciences. An industry consultant discusses the pay disparities, ways to fix the gaps and why change is needed.

April 23, 2026

5 min read

Angela Gabriel